In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Unimed, Inhale develop inhalable dronabinol

Executive Summary

Solvay Pharmaceuticals' Unimed Pharmaceuticals (cardiology, men's health, HIV, and other infectious diseases) unit and Inhale Therapeutic Systems (drug delivery) will develop a metered dose inhaler of dronabinol (synthetic delta-9-tetrahydrocannabinol) to treat a variety of disorders, using Inhale's Inhance pulmonary delivery platform.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies